GlassScriptPhysician profile
Tessa Green
NPI 1750133930
$1,381.90
in general payments reported to CMS, 2019-2025
15 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $304 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $357.87 | 2024-2025 | Auvelity, Symbravo, Sunosi |
| Paratek Pharmaceuticals, INC. | $234.39 | 2024-2025 | Nuzyra |
| Abbvie INC. | $213.62 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $116.68 | 2025 | Airsupra |
| Antares Pharma, INC. | $99.51 | 2024-2025 | Xyosted |
| Acella Pharmaceuticals, LLC | $64.15 | 2025 | NP Thyroid 60 |
| Lilly USA, LLC | $52.92 | 2025 | Mounjaro, Zepbound |
| Pfizer INC. | $51.69 | 2025 | |
| Azurity Pharmaceuticals, INC. | $45.91 | 2025 | Horizant |
| Novo Nordisk INC | $45.71 | 2025 | Wegovy |
| Idorsia Pharmaceuticals US INC | $23.73 | 2024 | Quviviq |
| Ibsa Pharma INC. | $23.66 | 2025 | Flector, Licart, Tirosint |
| Inspire Medical Systems, INC. | $18.32 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.43 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $16.31 | 2025 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tessa Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.